登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)
Study of SIM0518 in Participants With ALK-Positive or ROS1-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer
ClinicalTrials.gov 上登记的一项肺癌开放试验。牵头方不是本站收录的医院;本站收录的 6 家医院列为研究中心。
状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月18日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。
研究团队的联系方式见登记记录。本站不转递咨询。
列出这项试验的中国大陆医院 6
登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。
- 研究中心南昌大学第一附属医院First Affiliated Hospital of Nanchang University南昌医院页面
- 研究中心福建省肿瘤医院Fujian Cancer Hospital福州医院页面
- 研究中心哈尔滨医科大学附属肿瘤医院Harbin Medical University Cancer Hospital哈尔滨医院页面
- 研究中心湖南省肿瘤医院Hunan Cancer Hospital长沙医院页面
- 研究中心同济大学附属东方医院Shanghai East Hospital, Tongji University上海医院页面
- 研究中心上海市肺科医院Shanghai Pulmonary Hospital上海医院页面
登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心
来源:ClinicalTrials.gov 登记记录 NCT07912268,读取于 2026年11月18日;医院名称与本站医院名单匹配。 名称如何匹配
这项试验的核对清单 8
只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。
展开清单(8 项)收起清单
18 岁 至 未注明;性别:不限
登记记录的入选字段
Histologically and/or cytologically confirmed stage IIIB-IV non-curatively treatable (surgery, radiotherapy) Non-Small Cell Lung Cancer.
入选标准第 4 条
a: Cohort 1, Cohort 2, Cohort 4, and Cohort 5: disease progression or intolerance during/after treatment with at least one ALK inhibitor or a ROS1 inhibitor, with no more than 3 ALK/ROS1 inhibitors; and progression or intolerance after a maximum of one-line chemotherapy regimen.
入选标准第 8 条
Trial participants had symptomatic Central Nervous System metastases (CNS) metastases within 2 weeks prior to the first dose of study treatment, or CNS metastases requiring CNS-directed local therapy (e.g., radiotherapy or surgery) or corticosteroid therapy.
排除标准第 3 条
Uncontrollable or pleural effusion, pericardial effusion, or ascites requiring drainage or medical intervention within 4 weeks prior to the first dose of study treatment.
排除标准第 8 条
Trial participants with any active infection requiring systemic treatment by intravenous infusion within 2 weeks prior to start of study treatment.
排除标准第 9 条
Major surgery within 4 weeks prior to the first dose of study treatment.
排除标准第 21 条
Administration of strong or moderate CytochromeP450 3A4 (CYP3A4)inhibitors and/or strong CytochromeP450 2C8(CYP2C8) inhibitors ≤ 7 days or 5 half-lives (whichever is longer) prior to the first dose of study treatment;
排除标准第 22 条
Administration of strong or moderate CYP3A4 inducers ≤ 14 days or 5 half-lives (whichever is longer) prior to the first dose of study treatment;
排除标准第 23 条
Administer medications known to be at risk for torsades de pointes (TdP) ≤ 14 days or 5 half-lives, whichever is longer, prior to the first dose of study treatment;
排除标准第 24 条
Received anti-tumor antibody or Antibody-Drug Conjugate(ADC) therapy (whichever is shorter) within 4 weeks or 5 half-lives (whichever is shorter) before the first dose of study treatment.
排除标准第 28 条
Cytotoxic therapy, anti-tumor targeted small molecules (e.g. tyrosine kinase inhibitors) within 2 weeks prior to the first dose of study treatment.
排除标准第 29 条
Traditional Chinese medicine/traditional Chinese medicine preparations with anti-tumor indications within 2 weeks prior to the first dose of study treatment.
排除标准第 30 条
Traditional Chinese medicine/traditional Chinese medicine preparations (except topical medication) within 7 days prior to the first dose of study treatment.
排除标准第 31 条
(Part 3 Cohort 4 only) Study participants are expected to use any CYP3A4 inhibitor or inducer within ≤ 7 days (for 3A4 inhibitors) or ≤ 14 days (for 3A4 inducers) or 5 half-lives (whichever is longer) prior to the first dose of midazolam (as CYP3A4 probe substrate) until completion of the Drug-Drug Interaction(DDI)assessment on Cycle2Day2;
排除标准第 36 条
Eastern Cooperative Oncology Group Performance Status(ECOG) score 0 or 1.
入选标准第 10 条
NSCLC trial participants have driver gene mutations other than ALK/ROS1 that have corresponding marketed targeted agents, such as EGFR sensitivity mutations, HER2 mutations, KRASG12C mutations, BRAFV600 mutations, RET fusions, MET14 exon skipping mutations, MET amplifications, NTRK fusions.
排除标准第 2 条
Active or chronic hepatitis B (HBsAg or HBcAb positive and HBV DNA ≥ 2000 IU/mL or ≥ 10,000 copies/mL) or hepatitis C (HCV antibody positive and HCV RNA ≥ ULN) infection; trial participants who are HBsAg positive or HBV-DNA positive at screening should receive antiviral therapy during the study in accordance with local practice.
排除标准第 13 条
b: Presence of at least one measurable or evaluable tumor lesion per Response Evaluation Criteria in Solid Tumors, version 1.1.
入选标准第 7 条
b. Presence of at least one measurable lesion per RECIST 1.1; lesions previously irradiated cannot be considered target lesions unless the lesion progresses significantly.
入选标准第 9 条
Known human immunodeficiency virus (HIV) infection or known acquired immunodeficiency syndrome (AIDS).
排除标准第 12 条
Trial participants are pregnant or breastfeeding, or are expected to become pregnant or have children during the planned study.
排除标准第 33 条
勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:分期或严重程度(按试验的定义)。
按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT07912268,读取于 2026年11月10日。
登记的入选标准
依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。
入选标准:Inclusion Criteria:
Participants must meet all of the following inclusion criteria: Voluntary participation and signing of informed consent. Age ≥ 18 years, male or female. Histologically and/or cytologically confirmed stage IIIB-IV non-curatively treatable (surgery, radiotherapy) Non-Small Cell Lung Cancer. It was confirmed that trial participants carried ALK or ROS1 rearrangements from previous local test reports, in which testing was performed using kits approved by regulatory authorities. a: Heavily pretreated advanced. b: Presence of at least one measurable or evaluable tumor lesion per Response Evaluation Criteria in Solid Tumors, version 1.1. a: Cohort 1, Cohort 2, Cohort 4, and Cohort 5: disease progression or intolerance during/after treatment with at least one ALK inhibitor or a ROS1 inhibitor, with no more than 3 ALK/ROS1 inhibitors; and progression or intolerance after a maximum of one-line chemotherapy regimen. b. Presence of at least one measurable lesion per RECIST 1.1; lesions previously irradiated cannot be considered target lesions unless the lesion progresses significantly. Eastern Cooperative Oncology Group Performance Status(ECOG) score 0 or 1. Expected survival ≥ 12 weeks. Adequate organ and bone marrow function.排除标准:Exclusion Criteria:
Target disease to be excluded NSCLC trial participants have driver gene mutations other than ALK/ROS1 that have corresponding marketed targeted agents, such as EGFR sensitivity mutations, HER2 mutations, KRASG12C mutations, BRAFV600 mutations, RET fusions, MET14 exon skipping mutations, MET amplifications, NTRK fusions. Trial participants had symptomatic Central Nervous System metastases (CNS) metastases within 2 weeks prior to the first dose of study treatment, or CNS metastases requiring CNS-directed local therapy (e.g., radiotherapy or surgery) or corticosteroid therapy. The trial participant had spinal cord compression (due to tumor) unless the trial participant achieved good pain control by treatment and neurological function fully recovered within 4 weeks prior to the first dose. History of other active malignancies within the past 3 years with the following exceptions: adequately treated basal cell carcinoma or squamous cell skin cancer, carcinoma in situ of the breast or carcinoma in situ of the cervix, low-risk prostate cancer (Gleason score ≤ 6) under surveillance without any treatment intervention plan (e.g., surgery, radiotherapy, or castration therapy), and other concomitant malignancies assessed by the investigator in consultation with the sponsor as low risk of recurrence. Gastrointestinal disorders affecting drug administration/absorption: including dysphagia/inability to swallow the drug; major gastrointestinal surgery (e.g., bowel resection with clinically significant sequelae, total gastrectomy, etc.) affecting absorption; chronic diarrhea, symptomatic diverticulosis; subjects with active or persistent gastrointestinal bleeding, active peptic ulcer requiring treatment, or malabsorption syndrome within 180 days prior to signing the informed consent form; intestinal obstruction or other gastrointestinal disease that, in the opinion of the investigator, is not suitable for enrollment within 90 days prior to signing the informed consent form. Any psychiatric or cognitive disorder that may limit their understanding and execution of informed consent. Uncontrollable or pleural effusion, pericardial effusion, or ascites requiring drainage or medical intervention within 4 weeks prior to the first dose of study treatment. Trial participants with any active infection requiring systemic treatment by intravenous infusion within 2 weeks prior to start of study treatment. History of pneumonitis or interstitial lung disease requiring oral or intravenous steroids. Current interstitial lung disease or pneumonitis or suspected interstitial lung disease or pneumonitis at screening that cannot be screened by imaging. Trial participants had a history of active tuberculosis infection within 1 year; trial participants with a history of active tuberculosis, unless judged by the investigator to have no evidence of active tuberculosis for more than 1 year prior to the first dose of study treatment. Known human immunodeficiency virus (HIV) infection or known acquired immunodeficiency syndrome (AIDS). Active or chronic hepatitis B (HBsAg or HBcAb positive and HBV DNA ≥ 2000 IU/mL or ≥ 10,000 copies/mL) or hepatitis C (HCV antibody positive and HCV RNA ≥ ULN) infection; trial participants who are HBsAg positive or HBV-DNA positive at screening should receive antiviral therapy during the study in accordance with local practice. QTcF interval (corrected by Fridericia' s formula) > 450 milliseconds by electrocardiogram, hereditary long QT syndrome. Uncontrolled hyperglycemia, acute onset of cholelithiasis, or participants with susceptibility characteristics for acute pancreatitis as judged by the investigator within 28 days prior to the first dose. History of allogeneic organ transplantation or graft-versus-host disease. Known allergy to study drug or any excipients. Prior four-generation ALK inhibitors or ALK molecular gels. Has not recovered from an AE due to prior anti-tumor therapy. Currently participating in or participating in studies of other investigational drugs or investigational devices within 4 weeks prior to the first dose of SIM0518. Major surgery within 4 weeks prior to the first dose of study treatment. Administration of strong or moderate CytochromeP450 3A4 (CYP3A4)inhibitors and/or strong CytochromeP450 2C8(CYP2C8) inhibitors ≤ 7 days or 5 half-lives (whichever is longer) prior to the first dose of study treatment; Administration of strong or moderate CYP3A4 inducers ≤ 14 days or 5 half-lives (whichever is longer) prior to the first dose of study treatment; Administer medications known to be at risk for torsades de pointes (TdP) ≤ 14 days or 5 half-lives, whichever is longer, prior to the first dose of study treatment; Medications that may prolong the QT interval ≤ 14 days prior to the first dose of study treatment (TdP risk is uncertain); Proton pump inhibitors (PPIs) or H2 blockers were administered ≤ 7 days before the first dose of study treatment; Received the following anti-tumor therapies prior to the first dose of study treatment: Received anti-tumor antibody or Antibody-Drug Conjugate(ADC) therapy (whichever is shorter) within 4 weeks or 5 half-lives (whichever is shorter) before the first dose of study treatment. Cytotoxic therapy, anti-tumor targeted small molecules (e.g. tyrosine kinase inhibitors) within 2 weeks prior to the first dose of study treatment. Traditional Chinese medicine/traditional Chinese medicine preparations with anti-tumor indications within 2 weeks prior to the first dose of study treatment. Traditional Chinese medicine/traditional Chinese medicine preparations (except topical medication) within 7 days prior to the first dose of study treatment. Use of any live vaccines within 4 weeks prior to the first dose of study treatment. Trial participants are pregnant or breastfeeding, or are expected to become pregnant or have children during the planned study. Other circumstances considered unsuitable for inclusion by the investigator Additional Exclusion Criteria for Trial Participants in Part 3 (Drug Interaction Studies) (Part 3 Cohort 4 only) Study participants are expected to use any CYP3A4 inhibitor or inducer within ≤ 7 days (for 3A4 inhibitors) or ≤ 14 days (for 3A4 inducers) or 5 half-lives (whichever is longer) prior to the first dose of midazolam (as CYP3A4 probe substrate) until completion of the Drug-Drug Interaction(DDI)assessment on Cycle2Day2; (Part 3 Cohort 5 only) Study participants are expected to use inhibitors and inducers of any specific metabolic enzyme/transporter (CYP2B6, CYP2C8, CYP2C9, P-gp, and BCRP) within ≤ 7 days (inhibitor) or ≤ 14 days (inducer) or 5 half-lives (whichever is longer) prior to the first dose of the specific probe substrate to be used by trial participants until the completion of the DDI assessment on Cycle2Day2; . (Part 3 only) Trial participants with contraindications to the administration of the drug according to the current labeling of probe substrates (midazolam, bupropion, repaglinide, tolbutamide, fexofenadine, rosuvastatin) to be used in the cohort in which the trial participant is participating;
引自 ClinicalTrials.gov, NCT07912268, 参与标准,读取于 2026年11月10日。
这些信息从哪里来
登记记录
ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT07912268,读取于 2026年11月18日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。
疾病与医院
本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义
没有收录的内容
登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。